SR-T100 is full compliance to FDA standard regulations of Chemistry, Manufacturing & Controls. 80% complete response rate observed with phase II clinical trial study in Taiwan.
The mechanism & active component identified by High Performance Liquid Chromatography methods(±10%) served as our scienfific basis in this technology.Comparative study results showed SR-T100 has the least adverse effects among other similar products on the market (5-Fu, Imiquimod, Diclofenac & Ingenol Mebutate), complete elimination of actinic keratosis cells can be achieved in cryotherapy combination treatments, effectively prevents recurrence & suitable for treatment applications of actinic keratosis lesions in large skin surface areas.
Indication:common warts
Global patent registration in 2011 with preliminary data showing effective treatment against Verruca vulgaris (common warts), content ingredients found in G&E marketed cosmetics product lines were proven effective in discharge of unsightly spots, skin bumps & blisters with very low adverse reactions.
This particular application has approved by US FDA and Taiwan TFDA, and is currently processing the phase II clinical trial in Taiwan. Our market research study result shows no competing products encountered in clinical dermatology market.
Indication:genital warts
Global patent registation in 2011 with concurrent trial study results (January 2011 to April 2013) showing a high complete response & has the least adverse side effects compared with its counterpart medications on the market(Podofilox,lmiquimod & Veregen). This application has approved by US FDA and Taiwan TFDA, and is currently processing the phase II clinical trial in Taiwan.
